Metabolic Syndrome in PCOS: Precursors and Interventions

• Status: Completed
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to investigate the metabolic effects of anti-androgens and oral contraceptive pills (OCPs), compared with placebo, in the treatment of women with PCOS. We hypothesized that controlling elevated androgen levels with either anti-androgens or OCPs would produce improvement in metabolic markers in PCOS women and would reduce their long term metabolic risk.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northwestern University
• Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Treatments: Drospirenone; Estradiol; Estradiol 17 beta-cypionate; Estradiol 3-benzoate; Estradiol valerate; Ethinyl Estradiol; Flutamide; Polyestradiol phosphate

Criteria

Inclusion Criteria:

• 6 periods or fewer per year

• Overweight

• All ethnicities

Exclusion Criteria:

• Diabetes

• Heart Disease

• Chronic illness

• Regular Smokers

• Current use of Birth Control Pills, Patch, Ring, Depo